Curative strategies for high-risk acute promyelocytic leukemia

View Full Paper

Ask AI

Bookmark

Authors

Discussion

Review discusses optimal regimens for high-risk acute promyelocytic leukemia, indicating improved survival with ATRA-ATO combinations.

High-risk APL patients show improved survival with ATRA-ATO combinations, reducing early death rates.
Clinical trials demonstrate that ATRA-ATO-IDA surpasses ATRA-IDA in efficacy, highlighting regimen selection importance.
Induction, consolidation, and maintenance strategies should be tailored to individual patient needs in high-risk APL treatment.
Further research is essential to determine the optimal use of adjunctive therapies to combat complications like differentiation syndrome.

Chin et al. (2025) studied this question.

View Full Paper

Ask AI

Bookmark